Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. Abarelix
Peptide·plain sequence-like

Abarelix

ATLPC0035834

Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-N(Me)Tyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala-NH2

Routes
Compare in workbenchDownload releaseAPI JSON
  • Length
    18 aa
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Evidence landscape
  • 06 Product context
  • 07 Identity & reference map
  • 08 Data access & reproducibility
Coveragecounts only · not riskATLPC0035834
  • Measurements
    3
  • Endpoints
    3
  • Domains
    2/5
  • Products
    1
  • No matrix stability evidence
  • No clearance evidence
  • Product-level review pending
  • No sequence liability cues
Jump to domain

Open the matching evidence section below

All evidence index · 3
Exposure / Absorption
2 measurements
Distribution / Barrier
1 measurement
Metabolic & Proteolytic Stability
No evidence
Excretion / Persistence
No evidence
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

·
Identity view

A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.

Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-N(Me)Tyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala-NH2
Identity summarySpecific molecular form represented
Identity status
Specific molecular form represented
Residues
18
Peptidoform features
11
Documented molecular forms
1
Representations
2
Documented molecular forms1 form linked to this peptide identity
FormTopologyModificationsConnectionsRepresentationsMeasurements
ATLPF0038976—4—13
Residue view
Residue display
18 residues
A1C2notedD3X4XF5notedD6X7XS8N9T104-ClY11notedR12notedN13notedL14K15P16A17notedX18Me
Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

Reported residue markerpos 2
Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Non-standard residue tokenpos 4
X

Reported token 2Nal is not one of the 20 standard residue symbols in this display.

Stereochemistrypos 5
D-residue

D-residue notation reported as D-Phe; the parent residue is used for positional display.

Non-standard residue tokenpos 7
X

Reported token 3Pal is not one of the 20 standard residue symbols in this display.

Reported residue markerpos 11
Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported residue markerpos 12
Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Stereochemistrypos 13
D-residue

D-residue notation reported as D-Asn; the parent residue is used for positional display.

Stereochemistrypos 17
D-residue

D-residue notation reported as D-Ala; the parent residue is used for positional display.

Non-standard residue tokenpos 18
X

Reported token NH2 is not one of the 20 standard residue symbols in this display.

Residue modificationpos 10
4-Cl

Inline modification 4-Cl is reported on parent residue T10.

Residue modificationpos 18
Me

Inline modification Me is reported on parent residue X18.

Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.

Structure & chemistry

·
Chemical representationsequence / HELM only
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

ACDXFDXSNTYRNLKPAX
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached
3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modifications1 signal
FeaturePositionsInterpretationLink
Form-level topologyATLPF0038976Open-chain form. Residue-level connection endpoints are shown separately when available.Not linked
02

Physicochemical profile

6 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Physicochemical descriptors unavailable

These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Structure-derived (developability)

Computed from the representative peptidoform's chemical structure. Rule-of-5 / beyond-Ro5 framing per Lipinski/Doak.

Topological polar surface area
425.0 Ų
Computed logP (Crippen)
1.17

Computed logP — distinct from the measured logD endpoint.

Hydrogen-bond donors
13
Hydrogen-bond acceptors
16
Rotatable bonds
38
Rule-of-5 / beyond-Ro5 flags
Beyond bRo5

3 Ro5 violations · MW 1,416.09 Da

03

Exposure / Absorption

2 records

What evidence describes systemic exposure or absorption?

Evidence records
2
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
2
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
0
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeTmaxBioavailability
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
2
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
0
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Bioavailability1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

52 %

Eligible when experimental context matches

AUC-based relative bioavailability · human · plasma

Result: Reported point value · Molecular form: ATLPF0038976 · Route: intramuscular · Source: Primary reference linked

Reference
Tmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

259200 seconds

Eligible when experimental context matches

human

Result: Reported point value · Molecular form: ATLPF0038976 · Route: intramuscular · Source: Primary reference linked

Reference
04

Distribution / Barrier

1 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
1
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
1
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
0
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopePlasma protein binding
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
1
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
0
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Plasma protein binding1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

96-99 %

Eligible when experimental context matches

human · plasma

Result: Interval measurement · Molecular form: ATLPF0038976 · Source: Primary reference linked

Reference
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
0

barrier evidence

05

Evidence landscape

3 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain
Eligible when context matches
Interpret as reported
Supporting context only
Review before analysis
Exposure / Absorption
2 evidence records
2
0
0
0
Distribution / Barrier
1 evidence record
1
0
0
0
Metabolic & Proteolytic Stability
0 evidence records
0
0
0
0
Excretion / Persistence
0 evidence records
0
0
0
0
Toxicity / Safety
0 evidence records
0
0
0
0
Endpoint distribution

Top evidence-bearing endpoint questions.

Bioavailability
1
Plasma Protein Binding
1
Time To Max Concentration
1
Assay context

Broad context buckets, useful before comparing values.

In vivo / route
3
Traceability

Reference-link availability for measurement-level audit.

Linked reference
3
Not linked
0
All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

#ADMET domainEndpointReported valueResult typeAnalysis useAssay / modelConditionReference
1
Distribution / Barrier
Distribution
Plasma Protein Binding
96-99 %
Interval measurementEligible when experimental context matcheshuman · plasmaNot specified
Reference
Primary reference linked
2
Exposure / Absorption
Exposure
Time To Max Concentration
259,200 seconds
Reported point valueEligible when experimental context matcheshumanRoute: intramuscular
Reference
Primary reference linked
3
Exposure / Absorption
Exposure
Bioavailability
52 %
Reported point valueEligible when experimental context matchesAUC-based relative bioavailability · human · plasmaRoute: intramuscular
Reference
Primary reference linked
1–3 / 3
06

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

·
Summary1 linked product
Linked products
1
Label context
None
Clinical trials
5
Safety label cues
None
Linked products1 shown

Abarelix

Peptide-product match
Reviewed peptide match
Route / product class
Intramuscular Injection · Anti-Testosterone Agents
Clinical context
5 trial records · 1 exact intervention matches · latest 2026-03-11
Label safety context
No label safety cue linked
View product
07

Identity & reference map

3 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary2 reference groups
Identity type
modified or textual identity
Reported notation
0
Reference groups
2
Measurements
3
ATL peptide ID
ATLPC0035834
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 3
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 3
Different notation

Reported notation does not resolve to the current display sequence.

0 / 3
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

3 / 3
Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity
Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-N(Me)Tyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala-NH2
Reported names
No distinct human-readable aliases are exposed.
Reference map2 reference groups
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
DistributionExposure
Plasma Protein Binding, Time To Max Concentration
No reported alias
2 identity
2 evidence
Reference
Open
Exposure
Bioavailability
No reported alias
1 identity
1 evidence
08

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0035834
Identity type
modified or textual identity
ADMET endpoints
3
Evidence records
3
Reference groups
2
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0035834
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0035834' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.